263270-02-6

Basic information

• Product Name: 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER;TERT-BUTYL 5-BROMONICOTINATE;T-BUTYL 5-BROMO-3-PYRIDINECARBOXYLATE;T-BUTYL 5-BROMONICOTINATE;tert-Butyl 5-bromonicotinate 98%;5-Bromo-nicotinic acid tert-butyl ester;tert-butyl 5-bromopyridine-3-carboxylate;tert-Butyl5-bromonicotinate98%
• CAS NO: 263270-02-6
• Molecular Formula: C₁₀H₁₂BrNO₂
• Molecular Weight: 258.11
• Product Categories: blocks;Pyridines
• Mol File: 263270-02-6.mol

Chemical Properties

• Melting Point: 53-55
• Boiling Point: 279.8 °C at 760 mmHg
• Flash Point: 123 °C
• Appearance: /
• Density: 1.385 g/cm³
• Vapor Pressure: 0.00392mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Keep Cold
• PKA: 0.86±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER(263270-02-6)
• EPA Substance Registry System: 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER(263270-02-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 263270-02-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its versatile reactivity and stability make it an essential component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER serves as a crucial building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its unique properties contribute to the development of effective and environmentally friendly products.
Used in Organic Chemistry Research:
5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER is utilized as a valuable reagent in organic chemistry research. Its tert-butyl ester group allows for selective reactions and protection of the carboxylic acid functionality, facilitating the synthesis of complex organic molecules.
Used in Chemical Process Development:
As an important intermediate, 5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER is employed in the development of new chemical processes and methodologies. Its stability and reactivity enable the exploration of novel synthetic routes and the optimization of existing ones.
Used in Synthesis of Bioactive Compounds:
5-BROMO-3-PYRIDINECARBOXYLIC ACID TERT-BUTYL ESTER is used as a precursor in the synthesis of bioactive compounds, such as antimicrobial, antiviral, and anticancer agents. Its unique structure and reactivity contribute to the discovery of new therapeutic agents with improved efficacy and selectivity.

InChI:InChI=1/C10H12BrNO2/c1-10(2,3)14-9(13)7-4-8(11)6-12-5-7/h4-6H,1-3H3

Upstream product

• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 67098-46-8 O-tert-butyl-N,N-diisopropyl-isourea 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 887579-69-3 tert-butyl 5-cyanonicotinate 
• 1001755-36-7 tert-butyl 5-aminonicotinate 

Relevant articles and documents

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

A predictive model for additions to: N -alkyl pyridiniums

Disclosed in this communication is a thorough study on the dearomative addition of organomagnesium nucleophiles to N-alkyl pyridinium electrophiles. The regiochemical outcomes have observable and predictable trends associated with the substituent patterns on the pyridinium electrophile. Often, the substituent effects can be either additive, giving high selectivities, or ablative, giving competing outcomes. Additionally, the nature of the organometallic nucleophilic component was also investigated for its role in the regioselective outcome. The effects of either reactive component are important to both the overall reactivity and site of nucleophilic addition. The utility of these observed trends is demonstrated in a concise, dearomative synthesis of a tricyclic compound shown to have insecticidal activity. This journal is

NOVEL FERROPORTIN INHIBITORS

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Discovery of novel series of 6-benzyl substituted 4-aminocarbonyl-1,4- diazepane-2,5-diones as human chymase inhibitors using structure-based drug design

A novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5- diones were explored as human chymase inhibitors using structure-based drug design according to the X-ray cocrystal structure of chymase and compound 1. The optimization focused on

Preparation of 2-, 4-, 5-, and 6-aminonicotinic acid tert-butyl esters

Procedures are reported to prepare the tert-butyl esters of 2-aminonicotinic acid, 4-aminonicotinic acid, 5-aminonicotinic acid, and 6-aminonicotinic acid from 2-chloronicotinic acid, 4-chloronicotinic acid, 5-bromonicotinic acid, and 6-chloronicotinic acid, respectively, without need for purification of intermediates. Copyright

SEVEN-MEMBERED RING COMPOUND, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF

A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.

Substituted spirochromanone derivatives

The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of indole, 1H-indazole, 2H-indazole, 1H-thieno[2,3-c]pyrazole, 1H-pyrazolo[3,4-b]pyridine

SPIROCHROMANON DERIVATIVES

The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-b]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS

The invention relates to a compound of a formula (I): , or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders.

NICOTINAMIDE-BASED KINASE INHIBITORS

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating tyrosine kinase-associated disease states in a subject using a compound of